Caixin
Nov 09, 2022 05:35 AM
OPINION

Analysis: Will Scholz’s Visit Help BioNTech’s Covid Shot in China?

BioNTech delivered more than 2.6 billion doses to more than 165 countries and regions in 2021 and has signed orders to deliver 2.4 billion doses in 2022.
BioNTech delivered more than 2.6 billion doses to more than 165 countries and regions in 2021 and has signed orders to deliver 2.4 billion doses in 2022.

(Blue View) — Under a collaboration accord between China and Germany reached last week during German Chancellor Olaf Scholz’s visit to Beijing, BioNTech SE’s Covid-19 vaccine is to be made available to foreigners in China.

The agreement is seen as a potential first step toward offering the advanced mRNA shot more widely across the Chinese mainland. BioNTech’s China partner is Shanghai Fosun Pharmaceutical Group Co.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code